• Immunohistochemistry of rat tissue with Anti-CHN2 primary antibody (STJ500526) at 1:100 dilution in Buffer. Section was treated with DAB and Haematoxylin stain. Magnification is at 40X.

Anti-CHN2 antibody (150-180) (STJ500526)

SKU:
STJ500526-100

Shipping:
Free Shipping
Current Stock:
Host: Rabbit
Applications: ELISA/IHC/IP/WB
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-CHN2 (150-180) is suitable for use in ELISA, Immunohistochemistry, Immunoprecipitation and Western Blot research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Purification: Affinity Purified
Concentration: 0.68-0.71 µg/µl
Dilution Range: WB: 1:500
ELISA: 1:10, 000
IP: 1:200
IHC: 1:100
Storage Instruction: Store at-20°C for long term storage. Avoid freeze-thaw cycles.
Gene Symbol: CHN2
Gene ID: 1124
Uniprot ID: CHIO_HUMAN
Immunogen Region: 150-180
Immunogen: Synthetic peptide taken within amino acid region 150-180 on beta 2-chimaerin protein.
Tissue Specificity Highest levels in the brain and pancreas. Also expressed in the heart, placenta, and weakly in the kidney and liver. Expression is much reduced in the malignant gliomas, compared to normal brain or low-grade astrocytomas.
Function GTPase-activating protein for p21-rac. Insufficient expression of beta-2 chimaerin is expected to lead to higher Rac activity and could therefore play a role in the progression from low-grade to high-grade tumors.
Protein Name Beta-Chimaerin
Beta-Chimerin
Rho Gtpase-Activating Protein 3
Database Links Reactome: R-HSA-9013149
Cellular Localisation Membrane
Peripheral Membrane Protein
Alternative Antibody Names Anti-Beta-Chimaerin antibody
Anti-Beta-Chimerin antibody
Anti-Rho Gtpase-Activating Protein 3 antibody
Anti-CHN2 antibody
Anti-ARHGAP3 antibody
Anti-BCH antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance